Resmed (RSMDF) Research & Development (2009 - 2026)

Resmed has reported Research & Development for 18 years, with the latest figure at $94.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 12.3% year-over-year to $94.3 million; the trailing twelve-month figure through Mar 2026 stood at $359.0 million (up 10.22% YoY), and the FY2025 full-year result was $331.3 million, up 7.73% from the prior year.
• Research & Development for Q1 2026 stood at $94.3 million, up from $91.0 million in the prior quarter.
• The five-year high for Research & Development was $94.3 million in Q1 2026, with the low at $63.2 million in Q3 2022.
• Historically, Research & Development has averaged $78.2 million across 5 years, with a median of $78.1 million in 2023.
• Annual changes were most pronounced in 2023 — Research & Development increased 21.5% — and 2024, when it gained 0.83%.
• Resmed's Research & Development stood at $69.9 million in 2022, then gained by 5.73% to $73.9 million in 2023, then climbed by 10.14% to $81.4 million in 2024, then climbed by 11.79% to $91.0 million in 2025, then increased by 3.63% to $94.3 million in 2026.
• The last three Research & Development figures came in at $94.3 million (Q1 2026), $91.0 million (Q4 2025), and $87.3 million (Q3 2025), per Business Quant data.